The global human growth hormone market size is estimated to be USD 5,235.7 million in 2021 and is expected to witness a CAGR of 8.89% during the forecast period. Increase in application of growth hormones to control aging is a key driver for the growth of the global human growth hormone market. Additionally, rise in information about disorders related to growth hormone deficit and growing R&D investments in the human growth hormone market are some of the other drivers propelling the market growth. Nevertheless, side effects related with the growth hormone treatment and stringent regulatory situation in the developed economies are expected to restrain the global market growth.
Based on application, the market is segmented into Prader Willi syndrome, growth hormone deficiency, turner syndrome, idiopathic short stature, small for gestational age, and others. In 2021, the growth hormone deficiency segment accounted for the substantial revenue share with lucrative CAGR during the forecast period. This is attributed to growing awareness about early diagnosis and treatment of growth hormone deficiency in patients worldwide. Turner syndrome segment projected to grow at a profitable CAGR during the forecast period. This is attributed to the growing initiatives by various public and private organizations in development of technology for treating turner syndrome.
Based on route of administration, the market is categorized into oral, intravenous, intramuscular, and subcutaneous. In 2021, the subcutaneous segment accounted for the substantial revenue share with lucrative CAGR during the forecast period. This is due to the growth hormones administered subcutaneously are more bioavailability in comparison to other routes of administration worldwide. The oral segment is anticipated to grow at a profitable CAGR during the forecast period, due the launch of new products and shift towards oral drugs are the key factors driving the market worldwide.
Based on distribution channel, the market is categorized into retail pharmacy, hospital pharmacy, online pharmacy, and specialty pharmacy. In 2021, the hospital pharmacy segment accounted for the substantial revenue share with lucrative CAGR during the forecast period. This is due to the growing hospital visits due to rising awareness about growth hormone deficiencies among humans and the treatment available worldwide. The online pharmacy segment is anticipated to grow at a profitable CAGR during the forecast period, due the high rate of penetration of online pharmacies in developed regions.
In 2021, North America accounted for the highest revenue share in the global market and is expected to maintain its dominance during the forecast period. This is attributed to the favourable repayment scenarios, growth in initiatives from government, accessibility of technological advanced products in the region. Asia Pacific market is projected to exhibit the fastest CAGR over the forecast period owing to the less stringent regulations, growing government and corporate investment in healthcare sector, aged population, and availability of skilled labour forces at economic costs, are the major factors in this region. Competitor Insights Some of the key players in the human growth hormone market are Novo Nordisk A/S (Denmark); Pfizer, Inc. (U.S.); Eli Lilly and Company (U.S.); Sandoz International GmbH (Switzerland); Merck KGaA (Germany); Genentech, Inc. (U.S.); Ferring B.V. (Switzerland); Ipsen (France); Teva Pharmaceutical Industries, Ltd (Israel); and Anhui Anke Biotechnology (Group) Co., Ltd. (China). The leading players operating in the human growth hormone industry are adopting various strategies including R&D investments, adoption of advanced techniques, new technology launches, mergers & acquisitions, and regional expansions to capture a maximum revenue share.This exhaustive research report focuses on market size and forecast at global, segmental, regional and country level along with key market trends and dynamics from 2021 to 2029. The human growth hormone market report is categorized into the following segments and subsegments:
By Application
Based on application, the market is segmented into Prader Willi syndrome, growth hormone deficiency, turner syndrome, idiopathic short stature, small for gestational age, and others. In 2021, the growth hormone deficiency segment accounted for the substantial revenue share with lucrative CAGR during the forecast period. This is attributed to growing awareness about early diagnosis and treatment of growth hormone deficiency in patients worldwide. Turner syndrome segment projected to grow at a profitable CAGR during the forecast period. This is attributed to the growing initiatives by various public and private organizations in development of technology for treating turner syndrome.
By Route of Administration
Based on route of administration, the market is categorized into oral, intravenous, intramuscular, and subcutaneous. In 2021, the subcutaneous segment accounted for the substantial revenue share with lucrative CAGR during the forecast period. This is due to the growth hormones administered subcutaneously are more bioavailability in comparison to other routes of administration worldwide. The oral segment is anticipated to grow at a profitable CAGR during the forecast period, due the launch of new products and shift towards oral drugs are the key factors driving the market worldwide.
By Distribution Channel
Based on distribution channel, the market is categorized into retail pharmacy, hospital pharmacy, online pharmacy, and specialty pharmacy. In 2021, the hospital pharmacy segment accounted for the substantial revenue share with lucrative CAGR during the forecast period. This is due to the growing hospital visits due to rising awareness about growth hormone deficiencies among humans and the treatment available worldwide. The online pharmacy segment is anticipated to grow at a profitable CAGR during the forecast period, due the high rate of penetration of online pharmacies in developed regions.
Regional Insights
In 2021, North America accounted for the highest revenue share in the global market and is expected to maintain its dominance during the forecast period. This is attributed to the favourable repayment scenarios, growth in initiatives from government, accessibility of technological advanced products in the region. Asia Pacific market is projected to exhibit the fastest CAGR over the forecast period owing to the less stringent regulations, growing government and corporate investment in healthcare sector, aged population, and availability of skilled labour forces at economic costs, are the major factors in this region. Competitor Insights Some of the key players in the human growth hormone market are Novo Nordisk A/S (Denmark); Pfizer, Inc. (U.S.); Eli Lilly and Company (U.S.); Sandoz International GmbH (Switzerland); Merck KGaA (Germany); Genentech, Inc. (U.S.); Ferring B.V. (Switzerland); Ipsen (France); Teva Pharmaceutical Industries, Ltd (Israel); and Anhui Anke Biotechnology (Group) Co., Ltd. (China). The leading players operating in the human growth hormone industry are adopting various strategies including R&D investments, adoption of advanced techniques, new technology launches, mergers & acquisitions, and regional expansions to capture a maximum revenue share.This exhaustive research report focuses on market size and forecast at global, segmental, regional and country level along with key market trends and dynamics from 2021 to 2029. The human growth hormone market report is categorized into the following segments and subsegments:
Human Growth Hormone Market, By Application (Revenue, USD Million, 2021-2029)
- Prader-Willi Syndrome
Growth Hormone Deficiency
- Adult Growth Hormone Deficiency
- Paediatric Growth Hormone Deficiency
- Turner Syndrome
- Idiopathic Short Stature
- Small for Gestational Age
- Others
Human Growth Hormone Market, By Route of Administration (Revenue, USD Million, 2021-2029)
- Oral
- Intravenous
- Intramuscular
- Subcutaneous
Human Growth Hormone Market, By Distribution Channel (Revenue, USD Million, 2021-2029)
- Retail Pharmacy
- Hospital Pharmacy
- Online Pharmacy
- Specialty Pharmacy
Human Growth Hormone Market, By Region (Revenue, USD Million, 2021-2029)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- Saudi Arabia
- Rest of MEA
Table of Contents
1. Research Methodology
3. Executive Summary
4. Market Dynamics
5. Market Environment Analysis
6. COVID-19 Impact Analysis: Human Growth Hormone Market
7. Market Analysis by Application
8. Market Analysis by Distribution Channel
9. Regional Market Analysis
10. North America Human Growth Hormone Market
11. Europe Human Growth Hormone Market
12. Asia Pacific Human Growth Hormone Market
13. Latin America Human Growth Hormone Market
14. MEA Human Growth Hormone Market
15. Competitor Analysis
16. Company Profiles
Companies Mentioned
A selection of companies mentioned in this report includes:
- Novo Nordisk A/S (Denmark)
- Pfizer Inc. (U.S.)
- Eli Lilly and Company (U.S.)
- Sandoz International GmbH (Switzerland)
- Merck KGaA (Germany)
- Genentech Inc. (U.S.)
- Ferring B.V. (Switzerland)
- Ipsen (France)
- Teva Pharmaceutical Industries
- Ltd (Israel)
- Anhui Anke Biotechnology (Group) Co.
- Ltd. (China)
